Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
The discovery of immune checkpoint inhibitors and the advent of immune oncology has changed the way we think about cancer. Characterizing not only tumor biology but more so the immune system and tumor microenvironment, is now considered an essential part of oncology research and clinical decision making. We are driven to build new tools to accurately, comprehensively, and efficiently profile tumor tissue. We committed to delivering insights that drive new biomarkers, new therapies, and better treatments for cancer patients.
By combining highly sensitive exome-scale DNA and RNA sequencing, our NeoantigenID analytics engine delivers a comprehensive survey of putative neoantigens.
From a single tumor sample, InfiltrateID computes transcriptome-based enrichment scores for eight distinct immune cell types, quantifying the abundance of those populations within the TME.
Predicting response to immunotherapies requires a holistic understanding of the tumor and tumor microenvironment — and our technology is helping build effective biomarkers.
Purpose-built for your precision immuno-oncology applications, RepertoireID® interrogates the immune repertoire through RNA analysis.
